Asia Pacific Anaphylaxis Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Medication Type, Route of Administration, Allergy Type and Distribution Channel

Asia Pacific Anaphylaxis Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Medication Type, Route of Administration, Allergy Type and Distribution Channel

  • July 2021 •
  • 154 pages •
  • Report ID: 6134215 •
  • Format: PDF
The anaphylaxis treatment market in Asia Pacific is expected to grow from US$ 350.7 million in 2021 to US$ 664.0 million by 2028; it is estimated to grow at a CAGR of 9.6% from 2021 to 2028.

Novel drug delivery systems support improved drug potency and controlled drug release, along with imparting a sustained therapeutic effect for reliable safety.Many drugs have a maximum concentration range for maximum benefit, and concentrations above or below can be toxic or produce no medicinal use.

Further, various drug delivery and drug targeting systems are explained to have a capability of minimizing drug degradation as well as preventing harmful side effects.The intramuscular injection of epinephrine is normally underutilized when anaphylaxis occurs, mainly due to unavailability or unaffordability.

Drugs provide the convenience of a wide range of pain-free multiple doses, particularly for children, if required, for out-of-hospital emergency treatment of anaphylaxis.

Epinephrine needs to be administered in optimum quantities in the body at the time of anaphylaxis reaction, without wasting time.Therefore, companies are launching new products for fast delivery products for consumers.

For instance, in June 2018, INSYS Therapeutics, Inc. announced its investigational epinephrine nasal spray that has produced promising results in an early clinical trial as a potential needle-free, noninvasive, and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. Advancements in epinephrine drug delivery practices are assumed to make the patient’s lives easier. Children are more susceptible to acute allergic reactions and using injectors to treat them can be a challenging task. The novel drug delivery systems are being offered to assist in promoting the administration of an accurate number of drugs with secure handling.

The market for anaphylaxis treatment market is segmented into medication type, route of administration, allergy type, and distribution channel.Based on medication type, the anaphylaxis treatment market is segmented epinephrine, antihistamines, steroids, beta-agonist, and others.

In 2020, epinephrine segment accounted for the highest share of the market.The growth of the epinephrine is attributed due to easy access to the epinephrine, rising incidences of allergic reactions and growing government policies to access epinephrine to school-going children.

Additionally, the rise in the number of a product launch for generic version epinephrine is key factor responsible for the growth of the market. For instance, in July 2019, Sandoz, a Novartis AG division, has launched its generic pre-filled Symjepi epinephrine shots across the country.

Certainly, COVID-19 increases the risk of aggravating asthma and allergic diseases, but the government and private agencies are guiding for the treatments.According to guidelines of the Korean Academy of Asthma, Allergy and Clinical Immunology, and the Korean Academy of Pediatric Allergy and Respiratory Disease, detailed monitoring and optimal treatment with AIT, ICS, and biologics need to be continued in all patients who have asthma and allergic diseases.

This can be achieved in a safe condition using optimal protective measures.Patients at high risk (older age and comorbid conditions) should be monitored more strictly.

All the allergy/immunology specialists who strive to stay up for optimal health protection by focusing on patient management during the COVID-19 pandemic are necessary.As APAC passes through these challenging times of the COVID-19 pandemic, The Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) as an allergy/immunology community via its COVID-19 Task Force is carefully monitoring and updating Food and Drug Administration/Centers for Disease Control and Prevention/ WHO and other crucial scientific information on COVID-19 on its website COVID-19 resource section.

Thus, the rising need for allergy treatment is likely to boost the market.

The overall Asia Pacific anaphylaxis treatment market size has been derived using both primary and secondary sources.To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market.

The process also serves the purpose of obtaining overview and forecast for the Asia Pacific anaphylaxis treatment market with respects to all the segments pertaining to the region.Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic.

The participants who typically take part in such a process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the Asia Pacific Anaphylaxis treatment market. Amneal Pharmaceuticals Inc.; Mylan N.V.; Abbott; Pfizer Inc.; Glaxosmithkline Plc.; Merck and Co., Inc.; Teva Pharmaceutical Industries Ltd.; and ALK-ABELLó are among a few players operating in the Asia Pacific anaphylaxis treatment market.

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.